C-Peptide and 24-Hour Urinary C-Peptide as Markers to Help Classify Types of Childhood Diabetes

Katz, Lorraine E. Levitt

doi:10.1159/000430094

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those conditions were considered for C-peptide quantification in our protocol. Regarding the different assays for its determination, C-peptide could also be quantified after 8 to 10 h of fasting or after stimulation with glucagon, intravenous/oral glucose, tolbutamide, sulfonylurea, or a mixed meal [26], but these techniques are not effective in the presence of insulin treatment. Despite the fact that fasting C-peptide has been criticized due to its limited ability to detect subtle levels, other studies have proven that it correlates with urinary C-peptide [26].…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the different assays for its determination, C-peptide could also be quantified after 8 to 10 h of fasting or after stimulation with glucagon, intravenous/oral glucose, tolbutamide, sulfonylurea, or a mixed meal [26], but these techniques are not effective in the presence of insulin treatment. Despite the fact that fasting C-peptide has been criticized due to its limited ability to detect subtle levels, other studies have proven that it correlates with urinary C-peptide [26]. Urinary C-peptide levels had a high sensitivity for differentiating MODY from T1D or T2D [27], but had the disadvantage of being useful only in patients with adequate renal function.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA

Alemán-Contreras,

Gómez-Díaz,

Noyola-García

et al. 2024

Life

View full text Add to dashboard Cite

Background: The prevalence of obesity has increased in patients with type 1 diabetes (T1D) and latent autoimmune diabetes of the adult (LADA), limiting the use of clinical features such as the body mass index for its differentiation with type 2 diabetes (T2D). Additionally, some patients with maturity-onset diabetes of the young (MODY) or LADA are misdiagnosed as having T2D. The evaluation of autoantibodies and genetic testing are not fully available. We aimed to evaluate the utility of a widely available and less expensive diagnostic tool such as C-peptide to differentiate between T1D, T2D, MODY, and LADA. Methods: Our study included 38 patients with T1D, 49 with T2D, 13 with MODY, and 61 with LADA. We recorded anthropometric measurements, biochemical profiles, and antidiabetic treatment and determined C-peptide, anti-GAD65, and anti-IA2 antibodies. Results: C-peptide concentration differed significantly among populations (T1D: 0.2 ng/mL; T2D: 2.4 ng/mL; MODY: 1.14 ng/mL; LADA: 1.87 ng/mL). Through a ROC curve, we observed that the C-peptide cut-off point of 0.95 ng/mL allows differentiation between T1D and T2D (sensitivity 82%, specificity 77%); 0.82 ng/mL between T1D and LADA (sensitivity 82%, specificity 77%); and 1.65 ng/mL between T2D and MODY (sensitivity 72%, specificity 72%). Conclusions: C-peptide is useful for the diagnostic differentiation of patients with type 1, type 2 diabetes, MODY, and LADA.

show abstract

Section: Discussionmentioning

confidence: 99%